These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 3487823)

  • 1. Therapy with irritren in rheumatic degenerative diseases.
    Georgescu C; Dumitrescu C; Dănău M; Spandonidis S; Costache G
    Med Interne; 1986; 24(2):147-51. PubMed ID: 3487823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment of arthrosis with a new non-steroid anti-rheumatic agent (Voltaren). A double blind comparison with indomethacin].
    Wagenhäuser FJ; Narozna H
    Schweiz Med Wochenschr; 1975 May; 105(20):652-8. PubMed ID: 766164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Double blind trial involving: Teorema, a new antirheumatic, vs. indometacin in rheumatoid diseases.
    Petera P; Tausch G; Bröll H; Eberl R
    Int J Clin Pharmacol Biopharm; 1977 Dec; 15(12):581-4. PubMed ID: 340390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ["Double-blind" clinical study of a non-steroid anti-inflammatory drug: glucametacine].
    Pipino F; Franchin F
    Minerva Med; 1980 Oct; 71(39):2845-50. PubMed ID: 7001282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Action of the anti-inflammatory agent Lonazolac on experimentally-induced acute inflammation of human skin].
    Dethlefs J
    Z Rheumatol; 1978; 37(7-8):254-9. PubMed ID: 358658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preliminary double-blind evaluation of a new, non-steroidal anti-inflammatory drug: protacine.
    Münzenberg J; Tachibana S
    Pharmatherapeutica; 1980; 2(5):279-84. PubMed ID: 7001486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pyrasanone in the treatment of rheumatism].
    Pellegrini P; Colamussi V; Trotta F; Scaramelli M; Bazzanini G
    Minerva Med; 1975 Oct; 66(67):3509-33. PubMed ID: 1103007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short-term and long-term open evaluation of the efficacy and tolerance of proglumetacin, a new antirheumatic agent.
    Branco do Amaral A
    Pharmatherapeutica; 1982; 3(3):174-9. PubMed ID: 6982478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Anti-inflammatory therapy of rheumatic arthropathies with indomethacin].
    Ravetta A
    Clin Ter; 1972 Dec; 63(5):453-67. PubMed ID: 4566420
    [No Abstract]   [Full Text] [Related]  

  • 10. [2-(4-Isobutylphenyl)-propionic acid in the treatment of rheumatic diseases: clinical effects and tolerance].
    Viara M
    Minerva Med; 1973 Jun; 64(47):2513-4. PubMed ID: 4579843
    [No Abstract]   [Full Text] [Related]  

  • 11. [Gastroduodenal tolerance and clinical effectiveness of therapy with lonazolac-calcium in rheumatic diseases].
    Kullich W; Fromme K; Klein G
    Wien Med Wochenschr; 1996; 146(17):459-64. PubMed ID: 9045528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparative double blind study of pirprofen, indomethacin, and placebo in the treatment of osteoarthritis of the spine].
    Dolanc B; Morscher E
    Nouv Presse Med; 1982 Aug; 11(33):2500-2. PubMed ID: 7133973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Tolerability of pirprofen during prolonged treatment].
    David-Chaussé J
    Nouv Presse Med; 1982 Aug; 11(33):2522-4. PubMed ID: 6813823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Problems of rheumatic therapy in pregnancy (author's transl)].
    Bischof P
    MMW Munch Med Wochenschr; 1976 Oct; 118(41):1323-6. PubMed ID: 825725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of degenerative rheumatic diseases. Therapy of painful irritation-conditions of the spine and of periarthrosis using a new combination preparation].
    Gerhold H
    Fortschr Med; 1974 Aug; 92(22):958-61. PubMed ID: 4547109
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical study of a new anti-inflammatory drug: 4-prenyl-1,2-diphenyl-3,5-pyrazolidinedione (DA 2370).
    Dotti F; Ongari R; Carazzi R; Chierichetti S
    Arzneimittelforschung; 1972 Jan; 22(1):Suppl 1a:265-8. PubMed ID: 4553235
    [No Abstract]   [Full Text] [Related]  

  • 17. [Therapeutic efficacy of a new antirheumatic agent with optimal gastrointestinal tolerance: 2-phenyl-4,p-chlorophenyl-thiazol-5-ilacetic acid (Fentiazac)].
    Gorini M; Chizzi A; Dal Ri P; De Caro L
    Reumatismo; 1976; 28(1):15-29. PubMed ID: 1088315
    [No Abstract]   [Full Text] [Related]  

  • 18. [On the use in anti-rheumatic therapy of a new non-steroid anti-inflammatory agent: glucosamide of monohydrated (N-p-chloro-benzoyl-2-methyl-5-methoxy)-indol-3-acetic acid].
    De Arcangelis A
    Clin Ter; 1971 Nov; 59(3):229-39. PubMed ID: 5316735
    [No Abstract]   [Full Text] [Related]  

  • 19. Activity and tolerance of oxamethacin.
    Verhaegen H
    Methods Find Exp Clin Pharmacol; 1982; 4(8):617-23. PubMed ID: 6763119
    [No Abstract]   [Full Text] [Related]  

  • 20. [Therapy of rheumatic disease using a new antirheumatic drug].
    Weigel H
    Z Allgemeinmed; 1974 Nov; 50(33):1527-31. PubMed ID: 4549149
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.